Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer.

[1]  D. Yankelevitz,et al.  Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Cerfolio,et al.  Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. , 2003, The Journal of thoracic and cardiovascular surgery.

[3]  N. Altorki.  Celecoxib, a selective COX-2 inhibitor, enhances the response to preoperative Paclitaxel/Carboplatin in early stage lung cancer , 2003 .

[4]  H. Schäfers,et al.  Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. , 2003, The Annals of thoracic surgery.

[5]  A. Fischman,et al.  Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[6]  P. V. Van Schil,et al.  Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. , 2002, Lung cancer.

[7]  M. Graham,et al.  Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? , 2002, The Annals of thoracic surgery.

[8]  David R. Jones,et al.  Beneficial effects of inhaled nitric oxide in adult cardiac surgical patients. , 2002, The Annals of thoracic surgery.

[9]  S. Larson,et al.  An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. , 2002, The Annals of thoracic surgery.

[10]  G. Hobbs,et al.  Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. , 2001, Chest.

[11]  Y. Erdi,et al.  FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection , 2001, European Journal of Nuclear Medicine.

[12]  V Kalff,et al.  Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Richards,et al.  Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. , 2000, The Annals of thoracic surgery.

[14]  R. Rami-Porta,et al.  Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. , 2000, The Annals of thoracic surgery.

[15]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[16]  K. S. Lee,et al.  Primary tumors and mediastinal lymph nodes after neoadjuvant concurrent chemoradiotherapy of lung cancer: serial CT findings with pathologic correlation. , 2000, Journal of computer assisted tomography.

[17]  J Kotzerke,et al.  Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  P. Dupont,et al.  Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J Bogaert,et al.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Hustinx,et al.  Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  V. R. McCready,et al.  The mechanism of accumulation of tumour-localising radiopharmaceuticals , 1998, European Journal of Nuclear Medicine.

[22]  R. Coleman,et al.  Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. , 1997, AJR. American journal of roentgenology.

[23]  M. Kris,et al.  Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Kris,et al.  Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. , 1993, The Annals of thoracic surgery.

[25]  A. Rydholm,et al.  Limb-sparing surgery without radiotherapy based on anatomic location of soft tissue sarcoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.